MeSH term
Frequency | Condition_Probility | Humans | 114 | 0.0 |
Amino Acid Sequence | 19 | 0.0 |
Animals | 28 | 0.0 |
Complement 1/*metabolism | 5 | 19.0 |
Complement 1q/metabolism | 2 | 8.0 |
Complement Pathway, Classical/*physiology | 2 | 18.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Molecular Sequence Data | 18 | 0.0 |
Rats | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 59 | 0.0 |
*Alleles | 2 | 0.0 |
Cell Line, Transformed | 3 | 0.0 |
Flow Cytometry | 4 | 0.0 |
Precipitin Tests | 3 | 0.0 |
Transfection | 11 | 0.0 |
Tumor Cells, Cultured | 6 | 0.0 |
CD4-Positive T-Lymphocytes/immunology | 2 | 0.0 |
Cell Line | 16 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Cytotoxicity Tests, Immunologic | 3 | 0.0 |
*Cytotoxicity, Immunologic | 7 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 35 | 0.0 |
T-Lymphocytes, Cytotoxic/*immunology | 4 | 0.0 |
Alleles | 8 | 0.0 |
Base Sequence | 10 | 0.0 |
Blotting, Northern | 3 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Cloning, Molecular | 4 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Sequence Alignment | 2 | 0.0 |
Sequence Homology, Amino Acid | 3 | 0.0 |
Female | 22 | 0.0 |
Mice | 10 | 0.0 |
Dimerization | 2 | 0.0 |
Hydrolysis | 3 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Calcium/metabolism | 2 | 0.0 |
Complement/metabolism | 3 | 3.0 |
Complement Activation | 7 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 8 | 0.0 |
Glycosylation | 2 | 0.0 |
Kinetics | 5 | 0.0 |
Protein Binding | 6 | 0.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Umbilical Veins | 2 | 0.0 |
Complement 1r/*genetics | 2 | 50.0 |
English Abstract | 3 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Adult | 12 | 0.0 |
Aged | 10 | 0.0 |
Aged, 80 and over | 6 | 0.0 |
Alzheimer Disease/*metabolism | 2 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Male | 20 | 0.0 |
Middle Aged | 11 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Reference Values | 5 | 0.0 |
Complement 1q/*metabolism | 4 | 20.0 |
Ligands | 2 | 0.0 |
Solubility | 6 | 0.0 |
Complement/*analysis | 7 | 4.0 |
Pregnancy | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
DNA Primers | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
L Cells (Cell Line) | 2 | 0.0 |
Child | 4 | 0.0 |
Comparative Study | 11 | 0.0 |
Complement 3/analysis | 3 | 0.0 |
Superoxides/metabolism | 2 | 0.0 |
Complement Pathway, Classical | 3 | 2.0 |
Structure-Activity Relationship | 4 | 0.0 |
Blood Group Antigens/*genetics | 2 | 1.0 |
Blood Proteins/*genetics | 3 | 1.0 |
Gene Frequency | 5 | 0.0 |
Genetic Markers | 2 | 0.0 |
Complement/*biosynthesis/genetics | 2 | 25.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Autoimmunity/immunology | 2 | 6.0 |
Binding Sites | 6 | 0.0 |
Biological Transport | 2 | 0.0 |
Golgi Apparatus/metabolism | 2 | 1.0 |
Protein Conformation | 10 | 0.0 |
Disease Progression | 2 | 0.0 |
Swine | 2 | 0.0 |
Clone Cells | 2 | 0.0 |
Killer Cells, Natural/*immunology | 7 | 1.0 |
Complement 1r/*metabolism | 3 | 42.0 |
Complement 1s/*metabolism | 2 | 28.0 |
Cytotoxicity, Immunologic | 2 | 0.0 |
Histocompatibility Antigens Class I/*immunology | 3 | 2.0 |
Immunoglobulin G/immunology | 2 | 0.0 |
Macromolecular Substances | 9 | 0.0 |
Recombinant Proteins/immunology | 2 | 0.0 |
HLA-A2 Antigen/genetics/*immunology | 2 | 22.0 |
Isoantigens/*immunology | 2 | 2.0 |
Molecular Weight | 8 | 0.0 |
Immunoglobulin G/analysis | 3 | 0.0 |
Complement 1/*genetics | 3 | 60.0 |
Continental Population Groups | 3 | 1.0 |
Phenotype | 6 | 0.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
DNA Probes | 2 | 0.0 |
Sodium Dodecyl Sulfate | 2 | 3.0 |
Cattle | 3 | 0.0 |
Chromosomes, Human, Pair 12 | 3 | 1.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Skin/*metabolism | 2 | 1.0 |
Adolescent | 3 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Hemolysis | 9 | 2.0 |
Gene Frequency/genetics | 2 | 0.0 |
*Transfection | 3 | 1.0 |
Complement 1/deficiency | 2 | 40.0 |
Complement 2/deficiency | 3 | 13.0 |
Complement 4/deficiency | 2 | 8.0 |
Complement Pathway, Alternative | 3 | 2.0 |
In Vitro | 4 | 0.0 |
Mutation | 2 | 0.0 |
Plasmin/pharmacology | 2 | 11.0 |
Genes, Structural | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Histocompatibility Antigens Class I/genetics/*immunology | 2 | 7.0 |
Angioneurotic Edema/*immunology | 2 | 40.0 |
Ultracentrifugation | 2 | 1.0 |
Microscopy, Electron | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Isoelectric Focusing | 3 | 0.0 |
Japan | 2 | 0.0 |
Pedigree | 2 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
*Complement 1 | 5 | 55.0 |
*Complement Activation | 6 | 1.0 |
*Complement Pathway, Classical | 4 | 4.0 |
Complement 1r | 11 | 47.0 |
Monocytes/metabolism | 2 | 0.0 |
Complement Activating Enzymes/*genetics | 4 | 66.0 |
*Genetics, Population | 2 | 0.0 |
*Cloning, Molecular | 2 | 0.0 |
Complement 1/*analysis | 5 | 45.0 |
Guinea Pigs | 4 | 0.0 |
Complement 1q | 7 | 6.0 |
Complement 1s | 6 | 27.0 |
Chemistry | 3 | 1.0 |
Immunodiffusion | 5 | 1.0 |
Models, Molecular | 3 | 0.0 |
Calcium/pharmacology | 3 | 1.0 |
Complement 1/*physiology | 2 | 40.0 |
Complement 4/analysis | 2 | 0.0 |
Immunoelectrophoresis, Two-Dimensional | 2 | 1.0 |
Chromatography, Affinity | 2 | 0.0 |
Immunoglobulins/analysis | 2 | 0.0 |
Complement 3/metabolism | 2 | 0.0 |
Complement 4/metabolism | 2 | 2.0 |
Complement Inactivators | 2 | 10.0 |
Centrifugation, Density Gradient | 5 | 1.0 |
Iodine Radioisotopes | 2 | 0.0 |
Complement 1 Inactivators | 2 | 28.0 |
Complement Activating Enzymes/*metabolism | 2 | 6.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Enzyme Precursors/*metabolism | 2 | 1.0 |
Immunoelectrophoresis | 3 | 1.0 |
Rabbits | 4 | 0.0 |
Peptides/analysis | 2 | 2.0 |
Complement/*isolation & purification | 2 | 33.0 |
Immunoassay | 2 | 0.0 |
Complement/*physiology | 2 | 2.0 |
*Platelet Aggregation | 2 | 2.0 |
*Complement | 2 | 3.0 |
